Jennifer Mondillo
Adult Health · Schwenksville, PANPI 1366737660
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $285,885 of the $396,324 with a category attached, or 72.1%. Neurocrine Biosciences, Inc. accounts for 95.4% of it on its own, with 9 other manufacturers making up the rest. 2025 is the largest year on record at $172,483, more than ten times the $350 reported in 2021. Among adult health clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 497 payments — averaging $797.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$378K
- Otsuka America Pharmaceutical, Inc.$16K
- Acadia Pharmaceuticals Inc$1K
- E.r. Squibb & Sons, L.L.C.$387
- Urovant Sciences Inc$119
- Amgen$91
- plus $119 from 4 others
What the payments were for
- Consulting fees$42,01511%
- Speaking & faculty fees$285,88572%
- Travel & lodging$56,90414%
- Food & beverage$11,5193%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 442 | $378,045 |
| Otsuka America Pharmaceutical, Inc. | 31 | $16,349 |
| Acadia Pharmaceuticals Inc | 15 | $1,215 |
| E.r. Squibb & Sons, L.L.C. | 2 | $387 |
| Urovant Sciences Inc | 1 | $119 |
| Amgen | 1 | $91 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $55 |
| Sumitomo Pharma America, Inc. | 2 | $38 |
| ERMI LLC | 1 | $13 |
| Alpha Cognition USA, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$396,324 in reported general payments places this provider in the 95th percentile of 899 adult health providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MovantikNaloxegol Oxalate | 21 | $4,382 |
| Pioglitazone Hcl | 15 | $509 |
| Buspirone Hcl | 16 | $427 |
| Pravastatin Sodium | 14 | $389 |
| Escitalopram Oxalate | 24 | $358 |
| Amlodipine Besylate | 18 | $277 |
| Folic Acid | 12 | $69 |
Paid to pharmacies, not to this prescriber.
Other adult health in Schwenksville
- Beth SandyPhiladelphia$924K
- Diane NewmanPhiladelphia$343K
- Elizabeth FaustDouglassville$342K
- Abigail SmithPhiladelphia$302K
- Jean CainAllentown$214K
- Jennifer KeeleyWexford$97K
- Debra EvansFarrell$85K
- Bethann MallonBlue Bell$65K
- Catherine HoldsworthPhiladelphia$64K
- Melissa LaporteWilkes Barre$59K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.